Adam Wells, MD
Pulmonary Disease · Omaha, NENPI 1376863886
Payments from drug & device makers
What this record shows
This record is dominated by education: $19,100 of the $25,729 with a category attached, or 74.2%. Intuitive Surgical accounts for 81.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $16,579 and has fallen 86.4% since, to $2,247 in 2025. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $141.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$21K
- Sanofi$2K
- AstraZeneca$677
- Veran Medical Technologies, Inc.$261
- Grifols USA, LLC$259
- Johnson & Johnson$234
- plus $2K from 25 others
Across 9 payments — averaging $19,843 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$179K
What the payments were for
- Consulting fees$1,5816%
- Travel & lodging$1,1234%
- Food & beverage$3,92515%
- Education$19,10074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 24 | $20,882 |
| Sanofi | 7 | $1,813 |
| AstraZeneca | 18 | $677 |
| Veran Medical Technologies, Inc. | 2 | $261 |
| Grifols USA, LLC | 16 | $259 |
| Johnson & Johnson | 2 | $234 |
| GSK | 20 | $228 |
| Genentech USA, Inc. | 24 | $197 |
| Boehringer Ingelheim | 10 | $151 |
| Mallinckrodt Hospital Products Inc. | 3 | $144 |
| Covidien LP | 3 | $116 |
| Amgen | 5 | $95 |
| Sunovion Pharmaceuticals Inc. | 14 | $74 |
| United Therapeutics Corporation | 5 | $71 |
| Electromed, Inc. | 4 | $62 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 |
| Medtronic | 2 | $55 |
| Siemens Medical Solutions USA, Inc. | 1 | $43 |
| Harmony Biosciences LLC | 3 | $41 |
| Itamar Medical Inc | 1 | $35 |
| Philips North America LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Mylan Specialty L.p. | 2 | $30 |
| Insmed, Inc. | 2 | $28 |
| Boston Scientific | 1 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$15,000
- Da Vinci Surgical System$5,506
- FASENRA$385
- Spin$261
- BREZTRI$157
- TEZSPIRE$157
- Monarch Platform$118
- MONARCH$115
How this compares
$25,729 in reported general payments places this provider in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $299,826 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $160,118 |
| NucalaMepolizumab | 17 | $63,959 |
| Spiriva RespimatTiotropium Bromide | 36 | $33,689 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $33,468 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $31,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $28,529 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $20,324 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $7,366 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $5,749 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,275 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $3,853 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 160 | $3,737 |
| Ventolin HfaAlbuterol Sulfate | 16 | $859 |
| Roflumilast | 14 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $151 | $353,83993 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $228 | $289,138315 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $677 | $41,17070 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
- Lee MorrowOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.